# Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers

> **NCT05522335** · PHASE3 · UNKNOWN · sponsor: **Bharat Biotech International Limited** · enrollment: 3160 (actual)

## Conditions studied

- COVID-19 Respiratory Infection

## Interventions

- **BIOLOGICAL:** BBV154(Intranasal) & covaxin

## Key facts

- **NCT ID:** NCT05522335
- **Lead sponsor:** Bharat Biotech International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-16
- **Primary completion:** 2022-07-19
- **Final completion:** 2023-02-28
- **Target enrollment:** 3160 (ACTUAL)
- **Last updated:** 2022-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05522335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05522335, "Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05522335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*